- Press Release -

Rockville, Md. The global peptide based infection therapeutics market is set to near US$ 1.5 Bn by 2022 on robust growth, according to Fact.MR, as peptide agents emerge as novel treatments for infectious disease. Their advantages, safety, reliability, stability, high efficacy, cost-effectiveness and easy synthesis, are drawing investment, alongside rising foreign direct investment in emerging economies.

North America leads the market, telaprevir is the leading drug, and hospital pharmacies carry most sales. Asia Pacific excluding Japan is the fastest-growing region and online pharmacies the fastest channel.

Drugs, Channels and Regions

Telaprevir holds the larger share by drug class, though boceprevir grows faster at an 8.2% CAGR and, at that pace, could close the gap after 2022. On distribution, hospital pharmacies hold the largest revenue share, retail pharmacies rank second with faster growth, and online pharmacies grow fastest at a 9.2% CAGR from a smaller base.

North America is the most lucrative region and grows at an 8.4% CAGR, while Asia Pacific excluding Japan posts the fastest growth at an 8.7% CAGR on rapid development and foreign investment, with Europe close behind. Online pharmacies grow best in North America, while hospital and retail pharmacies are strongest in Asia Pacific and Europe.

Clinical Need Drives Demand

The market runs on the search for better infection treatments. As peptide agents prove their advantages over conventional options, and as biotech and pharmaceutical investment rises, demand builds steadily through the forecast period.

Suppliers and Their Playbook

The field brings together specialty chemical and pharmaceutical companies.

• Parchem Fine & Specialty Chemicals, Merck & Co., Inc., and Vertex Pharmaceuticals Incorporated are among the key players in the report.

Reading the Market for Decisions

For drug makers, growth favours established peptide drugs and a stronger online channel. Investors get a small market with robust, clinically led demand. Procurement and pharmacy teams can plan around hospital pharmacies leading distribution and North America offering the largest opportunity while Asia Pacific grows fastest through 2022.

About the Report

Fact.MR's study covers the global peptide based infection therapeutics market for the 2017 to 2022 forecast period, with segmentation by drug class, distribution channel and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the peptide based infection therapeutics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.